Laverock Therapeutics

Our CTO Tim Allsopp will be presenting a poster today at the American Society of Gene & Cell Therapy Annual Meeting ·      12:00, Exhibit Hall Poster #1377, Programmable Gene Silencing for Engineering Adaptable Cell Therapies, See the abstract here - https://lnkd.in/ddgN88dz Cell therapies are still facing considerable challenges relating to efficacy, safety and cost. A number of these challenges can be tackled by genetically engineering therapeutic cells so they respond to distinct cell state transitions and/or disease environments such as the tumour microenvironment (TME). Our poster highlights our new technology that enables programmable gene silencing to allow the engineering of programmable advanced therapies. Having already demonstrated silencing in human iPSCs in a tunable manner with no detectable off-target effects, we now show the ability to target genes in a developmental- and cell state-specific manner, in a range of human cells including primary T cells, iPSC-derived macrophages and iPSC-derived pancreatic cells. To find out more about Laverock Therapeutics’ uniquely powerful gene-silencing technology and how it can help in the creation of next-generation programmable advanced therapies get in touch via partnering, selecting a meeting hub located @ASGCT Central (open 12:00 to 19:00 in the Exhibit Hall, Booth #815) or via email at timothy.allsopp@laverocktx.com #ASGCT2024 #celltherapy #genetherapy #ASGCT #genesilencing #advancedtherapies

Our CEO David Venables is looking forward to attending EBD Group BioCentury Inc. #BioEquity next week, 12-14 May, in San Sebastian, Spain. It’s one of the key events on the European, and global, biotechnology calendars and we look forward to meeting investors and partners. We will also be giving a corporate presentation to provide an update on our progress with our uniquely powerful gene-silencing technology and how it can help in the creation of next-generation programmable advanced therapies. ·      Corporate Presentation in Cell & Gene Therapy Track – 14 May, 10:40, Room 4+5, Kursaal Elkargunea Center   We are open to partnering and investor meetings – contact us through the partnering system or email contact@laverocktx.com https://lnkd.in/dzunkQc #cellandgenetherapy #genesilencing #advancedtherapies

Our CTO Tim Allsopp will be in Baltimore next week at the American Society of Gene & Cell Therapy Annual Meeting from May 7 - 11. It’s the 27th Annual #ASGCT meeting and we’re looking forward to attending the world’s largest gathering of professionals in gene and cell therapy. We are open to meeting partners and investors and will also be presenting a poster on our truly innovative technology which harnesses the power of reprogramming the cell’s own gene control systems to develop advanced therapies that respond to specific cellular conditions and/or disease states. Get in touch via partnering, selecting a meeting hub located @ASGCT Central (open 12:00 to 19:00 in the Exhibit Hall, Booth #815) or via email at timothy.allsopp@laverocktx.com See our poster presentation (no. 1377) on 9 May at 12:00 in the Exhibition Hall. https://lnkd.in/ddgN88dz #ASGCT2024 #celltherapy #genetherapy #genesilencing #advancedtherapies https://lnkd.in/ea4XhZF

Our CEO David Venables will be joining a panel later today on ‘The Future of Genetic Medicine’ Alliance for Regenerative Medicine, Cell & Gene Meeting on the Med, in Rome. Moderated by Nina Bauer, PhD MBA, Chief Business Officer, SmartCella Holding AB and joined by speakers Behnam Ahmadian Baghbaderani, Vice President, Global Head of Commercial and Program Management, Lonza, Lisa Deschamps, CEO, AviadoBio, Kinnari Patel, PharmD, MBA, President and Chief Operating Officer, Rocket Pharmaceuticals and Richard Wilson, Senior Vice President, Primary Focus Lead, Genetic Regulation, Astellas Pharma, David and the panelists will explore how the landscape of genetic medicine is rapidly changing, driven by technological and scientific advances. This session will discuss the current state, future technologies and innovations, and solutions for manufacturing and regulatory bottlenecks as new genetic medicines move towards the clinic. Come along today April 10 at 4.15pm, Salone dei Cavalieri, Section 3&4 For the full agenda see - www.meetingonthemed.com Get in touch to find out more about Laverock Therapeutics’ uniquely powerful gene-silencing technology and how it can help in the creation of next-generation programmable advanced therapies – contact@laverocktx.com #CGMed24 #cellandgenetherapy #genesilencing #advancedtherapies

Our CEO David Venables and CTO Tim Allsopp are in Rome for Cell & Gene ‘Meeting on the Med’. They are looking forward to hearing about advances in the field, networking with industry colleagues, scientists and investors. If you’re at the conference come along tomorrow 9 April at 4.15pm to hear our corporate presentation by David Venables. He will provide an update on our progress with our uniquely powerful gene-silencing technology and how it can help in the creation of next-generation programmable advanced therapies. Get in touch to find out more – contact@laverocktx.com For the full agenda see - www.meetingonthemed.com #CGMed24 #cellandgenetherapy #genesilencing #advancedtherapies 

Our CEO David Venables and CTO Tim Allsopp will be at the Cell & Gene ‘Meeting on the Med’, 9-10 April in Rome. They are looking forward to hearing about advances in the field, networking with industry colleagues, scientists and investors. Organized by the Alliance for Regenerative Medicine, the three-day conference features more than 60 dedicated company presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies, as well as over 100 panelists and featured speakers. We are open to meeting partners and investors – get in touch via partnering or via email at contact@laverocktx.com See our presentation and panel ·        Corporate presentation - 9 April at 4.15pm ·        Panel – The future of Genetic Medicine - April 10 at 4.15pm For the full agenda see - www.meetingonthemed.com #CGMed24 #cellandgenetherapy #genesilencing #advancedtherapies #partnering

We are delighted to announce the expansion of our leadership team with the appointment of Ali Elsley as Finance Director. Ali brings 20 years-experience in the biotechnology and pharma sector having worked in house Acacia Pharma Group and in the Cambridge team of PwC covering audit and IPO advisory work for life science companies. Welcoming Ali to the team David Venables, CEO of Laverock, said: “Ali has an exceptional track record working with innovative biotechnology and pharma companies. I very much look forward to working closely with her and the rest of our fast-growing team as we continue to apply our uniquely powerful gene-silencing technology to the development of a new generation of programmable advanced therapies to tackle major diseases.” In recent months our team has grown significantly and now totals 24 people, representing growth of 50% over the past year, based in our expanded R&D facilities in the Stevenage Bioscience Catalyst. https://lnkd.in/dVcQvuQD #UKbiotech #Cambridge #appointment #finance #cellandgenetherapy #advancedtherapies #genesilencing

Up shortly at Advanced Therapies-live conference in London is our Team Leader, iPSC gene editing Anna Klucnika who will be presenting a poster on our uniquely powerful gene-silencing technology (Gene Editing induced Gene Silencing - GEiGS®), showing details of the platform, its features and benefits and how it can help in the creation of next-generation programmable advanced therapies. Come along to see her poster at 10.30: ‘Gene Editing induced Gene Silencing (GEiGS®) - A new platform for programmable cell engineering.’ Catch her or our COO Tom Payne at the conference or get in touch to find out more to find out more – contact@laverocktx.com   #adtherapies24 #cellandgenetherapy #advancedtherapies #genesilencing #GEiGS

Today our COO Tom Payne will be presenting at Advanced Therapies-live/ conference in London. He will share how our uniquely powerful gene-silencing technology (Gene Editing induced Gene Silencing - GEiGS®) can help in the creation of next-generation programmable advanced therapies.   Come along to hear his talk at 13.20: ‘Development of next-generation programmable cell therapies using gene editing induced gene silencing (GEiGS) technology.’ Catch him or our Team Leader, iPSC gene editing Anna Klucnika at the conference or get in touch to find out more to find out more – contact@laverocktx.com   #adtherapies24 #cellandgenetherapy #advancedtherapies #genesilencing #GEiGS

We are looking forward to Advanced Therapies live conference in London next week 19-20 March. We’ll be there to hear about advances in the field, network with industry colleagues, scientists and investors. Our COO Tom Payne will be presenting on day one and Team Leader, iPSC gene editing Anna Klucnika will be presenting a poster on day two. We will be sharing the key features and benefits of our uniquely powerful gene-silencing technology (Gene Editing induced Gene Silencing - GEiGS®) and how it can help in the creation of next-generation programmable advanced therapies. Catch them at the conference or get in touch to find out more – contact@laverocktx.com #adtherapies24 #cellandgenetherapy #advancedtherapies #genesilencing #GEiGS